ライフサイエンスコーパス: palliative treatment

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します

1 enerative disorder with no cure or effective palliative treatment.

2 causes), withdrawal of consent, or switch to palliative treatment.

3 watchful-waiting group have not required any palliative treatment.

4 wever, 4 Gy remains a useful alternative for palliative treatment.

5 e of emerging technologies for diagnosis and palliative treatment.

6 l therapeutic alternatives are available for palliative treatment.

7 onchoscopic lung volume reduction (bLVR) are palliative treatments aimed at reducing hyperinflation i

8 r, we reviewed the evidence on commonly used palliative treatments and their effect on quality of lif

9 Although several palliative treatments are available, there is currently

10 Effective and tolerable palliative treatments are needed for patients with incur

11 unately, most patients are suitable only for palliative treatment because of the extent of their tumo

12 ere for imaging studies; 68 (15.5%) were for palliative treatments, excluding chemotherapy or radiati

13 represents a major unmet medical need; only palliative treatments exist for this group of debilitati

14 ucocorticoid treatment represents a standard palliative treatment for Duchenne muscular dystrophy (DM

15 ume-reduction surgery has been proposed as a palliative treatment for severe emphysema.

16 better understand the benefits and burden of palliative treatments for patients with recurrent head a

17 ged 65 years and older deemed fit enough for palliative treatment had more toxicities or a worse outc

18 A variety of palliative treatments have evolved, but because of a low

19 en during sleep may be useful as a temporary palliative treatment in children with obstructive sleep

20 cure at presentation and those for whom only palliative treatment is possible.

21 nting has been reported to be effective as a palliative treatment, it is not curative.

22 fficacy outcomes for PRFE therapy use in the palliative treatment of both postoperative and nonpostop

23 a total cost of epidemic, including cost of palliative treatment of ill individuals and preventive c

24 red SEMS is an effective and safe method for palliative treatment of MBO.

25 eful adjunct to standard chemotherapy in the palliative treatment of metastatic breast cancer.

26 ith high-risk stage II and stage III cancer, palliative treatment of patients with metastatic disease

27 e three times higher than those recommending palliative treatment only (40.41 vs 12.19; p < 0.01).

28 mmendations for further medical treatment or palliative treatment only at the end of life may influen

29 commend continuing full medical treatment or palliative treatment only.

30 fosine solution is confirmed as an effective palliative treatment option for cutaneous metastases fro

31 s with metastatic breast cancer because many palliative treatment options are available.

32 ng with emotion, (6) describing surgical and palliative treatment options, (7) eliciting patient's go

33 h metastatic prostate carcinoma who received palliative treatment that did and did not include 89Sr-c

34 Unfortunately, other than palliative treatments there is no effective therapy for

35 antly shorter progression-free survival upon palliative treatment with cetuximab plus chemotherapy or

36 thin a neighborhood of certain size and only palliative treatment with no prevention.

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。